{"groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"FG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"FG001","title":"Docetaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"126"},{"groupId":"FG001","numSubjects":"53"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"16"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"301"},{"groupId":"FG001","numSubjects":"152"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"298"},{"groupId":"FG001","numSubjects":"140"}],"comment":"Participants who received at least one dose of study treatment.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"comment":"Patients who crossed over from Docetaxel to Adagrasib are included in the Docetaxel arm only.","groupId":"FG001","numSubjects":"44"}],"comment":"Eligible participants receiving Docetaxel based on physician switched to treatment with Adagrasib","type":"Cross Over"},{"achievements":[{"groupId":"FG000","numSubjects":"163"},{"groupId":"FG001","numSubjects":"83"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"138"},{"groupId":"FG001","numSubjects":"69"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}